Literature DB >> 12730101

Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells.

Delphine Sauce1, Nathalie Rufer, Patricia Mercier, Marie Bodinier, Jean-Paul Rémy-Martin, Anne Duperrier, Christophe Ferrand, Patrick Hervé, Pedro Romero, François Lang, Pierre Tiberghien, Eric Robinet.   

Abstract

To modulate alloreactivity after hematopoietic stem cell transplantation, "suicide" gene-modified donor T cells (GMCs) have been administered with an allogeneic T-cell-depleted marrow graft. We previously demonstrated that such GMCs, generated after CD3 activation, retrovirus-mediated transduction, and G418 selection, had an impaired Epstein-Barr virus (EBV) reactivity, likely to result in an altered control of EBV-induced lymphoproliferative disease. To further characterize the antiviral potential of GMCs, we compared the frequencies of cytomegalovirus (CMV)-specific CD8+ T (CMV-T) cells and EBV-specific CD8+ T (EBV-T) cells within GMCs from CMV- and EBV-double seropositive donors. Unlike anti-EBV responses, the anti-CMV responses were not altered by GMC preparation. During the first days of culture, CMV-T cells exhibited a lower level of CD3-induced apoptosis than did EBV-T cells. In addition, the CMV-T cells escaping initial apoptosis subsequently underwent a higher expansion rate than EBV-T cells. The differential early sensitivity to apoptosis could be in relation to the "recent activation" phenotype of EBV-T cells as evidenced by a higher level of CD69 expression. Furthermore, EBV-T cells were found to have a CD45RA-CD27+CCR7- effector memory phenotype, whereas CMV-T cells had a CD45RA+CD27-CCR7- terminal effector phenotype. Such differences could be contributive, because bulk CD8+CD27- cells had a higher expansion than did bulk CD8+CD27+ cells. Overall, ex vivo T-cell culture differentially affects apoptosis, long-term proliferation, and overall survival of CMV-T and EBV-T cells. Such functional differences need to be taken into account when designing cell and/or gene therapy protocols involving ex vivo T-cell manipulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730101     DOI: 10.1182/blood-2002-11-3407

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

1.  Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Authors:  Yun Lin; Humilidad F Gallardo; Geoffrey Y Ku; Hao Li; Gregor Manukian; Teresa S Rasalan; Yinyan Xu; Stephanie L Terzulli; Lloyd J Old; James P Allison; Alan N Houghton; Jedd D Wolchok; Jianda Yuan
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

2.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

3.  Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Authors:  E Bôle-Richard; C Gamonet; J-M Certoux; I Idirene; F Larosa; E Deconinck; A-M Mosseley; P Tiberghien; C Borg; C Ferrand; M Deschamps
Journal:  Gene Ther       Date:  2016-05-12       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.